Clinical bottom line
Early intervention strategies in autoimmune neuromyelitis optica spectrum disorder (NMOSD) targeting both cognitive and motor symptoms show promise in reducing relapse frequency and mitigating disability progression. Immunosuppressive therapies such as rituximab and azathioprine remain mainstays, with emerging complement inhibition (eculizumab) offering additional benefit. However, evidence specifically addressing early cognitive and motor symptom management is limited, warranting cautious interpretation. Clinicians should consider early diagnosis and initiation of immunotherapy to potentially improve neurological outcomes, while monitoring for treatment-related risks.
What the evidence shows
NMOSD is an autoimmune inflammatory disorder primarily affecting the optic nerves and spinal cord, often presenting with motor deficits and cognitive impairment secondary to recurrent demyelinating attacks (Smith et al., 2021; Raymond et al., 2024). Early diagnosis is critical, as delayed treatment correlates with worse neurological outcomes (Jorge Rodrigo et al., 2021). Immunosuppressive therapies, particularly rituximab and azathioprine, have demonstrated efficacy in reducing relapse rates and stabilizing motor function (Shaygannejad et al., 2017). The randomized clinical trial by Shaygannejad et al. (2017) showed rituximab had superior efficacy compared to azathioprine in relapse prevention, which may indirectly preserve cognitive function by limiting CNS damage.
More recently, complement inhibition with eculizumab has been reviewed as a targeted therapy for NMOSD, showing significant reduction in relapse risk in AQP4-IgG seropositive patients (Eculizumab review, 2020). While these therapies primarily focus on relapse prevention, early intervention may also attenuate cognitive decline and motor disability by minimizing cumulative CNS injury.
Radiological studies underscore the importance of early intervention; spinal cord lesions and brain involvement correlate with motor and cognitive symptoms (Gaillard et al., 2012; Naung Hein et al., 2026). Advanced imaging can aid in early detection and monitoring of disease progression (Raymond et al., 2024). However, specific trials evaluating cognitive rehabilitation or neuroprotective strategies in NMOSD remain sparse.
Caveats and uncertainty
The evidence base for early intervention specifically targeting cognitive and motor symptoms in NMOSD is limited. Most clinical trials focus on relapse prevention rather than direct symptomatic management. Cognitive impairment in NMOSD is less well characterized than in multiple sclerosis, and standardized assessment tools are lacking. The heterogeneity of NMOSD phenotypes and antibody status (AQP4-IgG positive vs negative) complicates generalization of findings.
Long-term safety data for newer agents like eculizumab are still evolving, and cost and accessibility may limit widespread use. Additionally, the impact of early immunotherapy initiation on cognitive outcomes remains largely hypothesis-generating, requiring prospective validation.
How this may change practice
Neurologists should maintain a high index of suspicion for NMOSD in patients presenting with acute motor deficits and visual symptoms, facilitating early diagnosis and treatment initiation. Incorporating early immunosuppressive therapy, particularly rituximab or azathioprine, may reduce relapse frequency and preserve neurological function (Shaygannejad et al., 2017).
Emerging therapies such as eculizumab offer promising options for refractory cases or those with severe disease, but require careful patient selection and monitoring (Eculizumab review, 2020). Clinicians should also consider early neuropsychological assessment to identify cognitive deficits and tailor supportive care, although evidence-based cognitive rehabilitation protocols specific to NMOSD are not yet established.
Multidisciplinary management including rehabilitation specialists may optimize motor recovery and quality of life. Further research is needed to define the role of early intervention strategies directly targeting cognitive and motor symptoms beyond relapse prevention.